Strategies for research capacity building by family physicians in primary healthcare: a scoping review protocol.

INTRODUCTION: The qualities of primary healthcare (PHC) make it a very relevant environment for research; however, there is still work to be done to enhance the research capabilities of family physicians in healthcare units. Considering there is no ongoing review that specifically addresses this objective, the proposed goal of this scoping review is to determine the depth of the literature on the current strategies that support research capacity building among family physicians in the context of PHC. METHODS AND ANALYSIS: The scoping review will include studies from PubMed, Scopus, Web of Science, Cochrane Library and grey literature, published from 2008 to 2023, that address strategies to promote research capacity building among family physicians in the context of PHC. Only studies published in English, Portuguese or Spanish will be considered. All study designs, including quantitative, qualitative and mixed-methods studies, will be eligible for inclusion. The literature search will be performed from January to March of 2024 and data charting will employ a descriptive-analytical method, systematically summarising study objectives, methodologies, findings and implications. This protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols and the review will employ the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews. ETHICS AND DISSEMINATION: This review does not need ethical approval. Peer-reviewed publications, policy summaries, presentations at conferences and involvement with pertinent stakeholders are all part of our outreach approach.

Barriers to research in family medicine-interviews with Portuguese family physician researchers.

BACKGROUND: There is a need for a deeper understanding of the barriers to research in family medicine (FM) and to consider the perceptions and perspectives of professionals. Our study aims to provide a strategic view for research capacity building in FM. We included the perspective of family physician researchers (FPR) on the existing barriers to investigation in this context. OBJECTIVES: To understand and characterize the barriers to research in FM (personal and structural), from the perspective of Portuguese family physicians who are researchers. METHODS: A qualitative study, of phenomenological nature, was performed, through the conduction of semi-structured interviews with FPR, from 2019 to 2022. Data analysis and thematic coding were done on MAxQDA®, with inductive and deductive approaches, until data saturation was reached. RESULTS: A total of 12 family physicians/researchers were interviewed. Seven main themes were identified as barriers to research: time, professional valorization, funding, ethics committees, infrastructure, management/institutions, and participants. Each theme is divided into subthemes that make it possible to assess how a barrier can affect researchers in performing research activities. CONCLUSION: Our study highlights the identification of 7 main barriers. Structuring them into sub-themes not only improved the organization of our results but also provided robust support for the next phase, namely the application of a survey with the aim of gaining a deeper insight into the repercussions that these barriers to FPR have at a national level. This research is crucial to laying the foundations for a policy document that offers well-defined and tailored recommendations to address the barriers we have uncovered.

[Prescribing Trends of Benzodiazepine and other Sedatives in the Lisbon and Tagus Valley Regional Health Administration between 2013 and 2020: A Retrospective Study]. / Prescrição de Benzodiazepinas e outros Sedativos na Administração Regional de Saúde de Lisboa e Vale do Tejo de 2013 a 2020: Um Estudo Retrospetivo.

INTRODUCTION: Among the Organization for Economic Co-operation and Development members, Portugal has the highest reported consumption of anxiolytics, hypnotics, and sedatives, of which a large proportion are benzodiazepines or related drugs. These are known to cause tolerance and dependence. Other drugs with hypnotic effect, such as antidepressants, antihistamines, antipsychotics, or anticonvulsants have been identified by some reports as alternatives to benzodiazepines for the treatment of insomnia. In this regard, the aim of this study was to characterize the consumption of benzodiazepines, non-benzodiazepine anxiolytic, hypnotic or sedative effect drugs and other drugs with the potential to be used off-label to treat insomnia, and the results concerning benzodiazepine consumption related indicators in the primary health care setting in the Lisbon and Tagus Valley region. MATERIAL AND METHODS: From 2013 to 2020, a census, descriptive and retrospective study was conducted. The evolution of the variables total defined daily doses, defined daily doses per 1000 inhabitants per day (DHD) and relevant indicators were characterized. Data were extracted from the SIARS platform used in the Lisbon and Tagus Valley regional Health Administration. RESULTS: There was a decrease in the consumption of benzodiazepines (from 57.44 to 63.11 DHD) and an increase of non-benzodiazepines and of drugs with potential off-label use (from 6.56 to 8.56 DHD and from 14.70 to 25.95 DHD, respectively). Among non-benzodiazepines, zolpidem was the most consumed drug, also showing an increasing trend (from 4.86 to 6.96 DHD). For the group of drugs with off-label use potential, there was an increased consumption of trazodone (from 3.81 to 7.92 DHD), mirtazapine (from 3.52 to 6.48 DHD), pregabalin (from 3.15 to 4.87 DHD), quetiapine (from 2.68 to 4.59 DHD) and gabapentin (from 1.32 to 1.90 DHD), which was only the case (or, at least, more significantly) for the lower dose formulations. The median of results of the Primary Health Care setting indicator "proportion of elderly patients without prescription of sedatives, anxiolytics, and hypnotics", was 81.0 in 2015 and increased to 84.9 in 2020. For the indicator "proportion of patients without prolonged prescription of sedatives, anxiolytics, and hypnotics", the median was 93.6 in 2019 and 94.3 in 2020. CONCLUSION: There was, overall, a decreasing trend in the dispensing of benzodiazepines in the Lisbon and Tagus Valley Region. Even though this data suggests a change in the therapeutic pattern for insomnia, more robust studies are needed to confirm this observation.

Introdução: Portugal é o país da Organização para a Cooperação e Desenvolvimento Económico com maior consumo de ansiolíticos, hipnóticos e sedativos, sendo uma proporção significativa constituída por benzodiazepinas ou análogos, associados a efeitos de tolerância e dependência. Por este motivo, em alternativa às benzodiazepinas para tratamento da insónia, algumas publicações identificam outros fármacos com efeito hipnótico, como antidepressivos, anti-histamínicos, antipsicóticos ou anticonvulsivantes. Assim, torna-se necessário compreender a evolução do consumo destes medicamentos, pelo que foi objetivo deste estudo avaliar a evolução da dispensa de benzodiazepinas, outros fármacos ansiolíticos, hipnóticos ou sedativos não benzodiazepínicos, fármacos com potencial uso off-label na insónia e os resultados de indicadores dos Cuidados de Saúde Primários neste âmbito na região de Lisboa e Vale do Tejo. Material e Métodos: Realizou-se um estudo em base de dados, censitário e retrospetivo, no período de 2013 até 2020, avaliando-se a evolução das variáveis total de doses diárias definidas, doses diárias definidas por 1000 habitantes por dia (DHD) e dos indicadores relevantes. Os dados foram extraídos da plataforma SIARS da Administração Regional de Saúde de Lisboa e Vale do Tejo. Resultados: Verificou-se uma diminuição da dispensa de benzodiazepinas (de 57,44 para 51,77 DHD) mas o aumento da dispensa de não benzodiazepinas e de fármacos com potencial uso off-label (de 6,56 para 8,56 DHD e de 14,70 para 25,92 DHD, respetivamente). O zolpidem foi o mais dispensado entre os fármacos não benzodiazepínicos, acompanhando a tendência crescente de dispensa (de 4,86 para 6,96 DHD). Do conjunto de fármacos com potencial para uso off-label verificaram-se aumentos da dispensa para a trazodona (de 3,81 para 7,92 DHD), mirtazapina (de 3,52 para 6,48 DHD), pregabalina (de 3,15 para 4,87 DHD), quetiapina (de 2,68 para 4,59 DHD) e gabapentina (de 1,32 para 1,90 DHD), mas mais significativo ou apenas verificado nas formulações com dosagem mais baixa. A mediana dos resultados do indicador "proporção de idosos sem prescrição de sedativos, ansiolíticos e hipnóticos" em 2015 foi de 81,0, tendo em 2020 aumentado para 84,9. A mediana do indicador "proporção de utentes sem prescrição prolongada de ansiolíticos, sedativos e hipnóticos" em 2019 foi de 93,6 e aumentou para 94,3 em 2020. Conclusão: Globalmente, verificou-se uma redução da dispensa de benzodiazepinas prescritas na Região de Lisboa e Vale do Tejo. Parece existir uma alteração do padrão de prescrição no tratamento da insónia. São necessários estudos mais robustos para confirmar esta observação.

Current costs of heart failure in Portugal and expected increases due to population aging. / Os custos da insuficiência cardíaca em Portugal e a sua evolução previsível com o envelhecimento da população.

INTRODUCTION AND OBJECTIVES: Heart failure (HF) is a growing public health problem. This study estimates the current and future costs of HF in mainland Portugal. METHODS: Costs were estimated based on prevalence and from a societal perspective. The annual costs of HF included direct costs (resource consumption) and indirect costs (productivity losses). Estimates were mostly based on data from the Diagnosis-Related Groups database, real-world data from primary care, and the opinions of an expert panel. Costs were estimated for 2014 and, taking population aging into account, changes were forecast up to 2036. RESULTS: Direct costs in 2014 were €299 million (39% for hospitalizations, 24% for medicines, 17% for exams and tests, 16% for consultations, and the rest for other needs, including emergencies and long-term care). Indirect costs were €106 million (16% for absenteeism and 84% for reduced employment). Between 2014 and 2036, due to demographic dynamics, total costs will increase from €405 to €503 million. Per capita costs are estimated to rise by 34%, which is higher than the increase in total costs (+24%), due to the expected reduction in the resident population. CONCLUSIONS: HF currently has a significant economic impact, representing around 2.6% of total public health expenditure, and this is expected to increase in the future. This should be taken into account by health policy makers, alerting them to the need for resource management in order to mitigate the impact of this disease.

[Multimorbidity and Disease Severity Measured by the Charlson Index in Portuguese Hospitalised Patients During the Year 2015: A Cross-Sectional Study]. / Multimorbilidade e Gravidade da Doença Medida pelo Índice de Charlson em Doentes Hospitalizados Durante o Ano de 2015: Estudo Transversal.

INTRODUCTION: The association between multimorbidity and disease severity is not well established. The objectives were to characterise multimorbidity and determine disease severity (trough Charlson), as well as to verify if there is an association between the number and type of disease and the Charlson index. MATERIAL AND METHODS: A cross-sectional study based on exported data from the Portuguese National Health Service hospitalisations database, during the year 2015. The study included 22 chronic health conditions: 15 predicted in the Charlson index and seven frequent conditions (hypertension, obesity, dyslipidaemia, osteoarthritis, osteoporosis, anxiety and depression). The analysis was performed through the generalised linear model, considering binary logistic regression. In the analysis, the IBM SPSS version 24.0 tool was used. RESULTS: The study analysed 800 376 hospitalisations, from which 42% correspond to males. The average age of the sample was 59.8 years, being higher in men (62.3 years). The mean number of problems per person was 1.6, greater in men (1.8). Disease severity was also higher in males. The worst prognosis was associated with six or more conditions per person. The largest predictor of disease severity was the number of problems, followed by dementia and diabetes. DISCUSSION: The results seem to confirm the gender difference regarding morbidity pattern. The number of conditions per person was the greatest predictor of disease severity, particularly the presence of six or more conditions per person. CONCLUSION: The major limitation was the use of the same medical conditions to measure multimorbidity and disease severity. Other studies and analysis models should explore the complexity of the multimorbidity phenomenon.

Introdução: A associação entre multimorbilidade e gravidade da doença não está bem estabelecida. Os objetivos foram caracterizar a multimorbilidade e determinar a gravidade da doença, bem como verificar se existe associação entre o número e natureza dos diagnósticos e o índice de Charlson. Material e Métodos: Estudo transversal realizado através de dados exportados da base de dados de internamentos, durante o ano de 2015. O estudo incluiu 22 doenças crónicas: 15 previstas no índice de Charlson e sete condições médicas frequentes (hipertensão, obesidade, dislipidemia, osteoartrose, osteoporose, ansiedade e depressão). A análise foi realizada através do modelo linear generalizado, regressão logística binária. Na análise, utilizou-se a ferramenta IBM SPSS versão 24.0. Resultados: Foram analisadas 800 376 hospitalizações, das quais 42% correspondem a homens. A idade média da amostra foi de 59,8 anos, sendo maior nos homens (62,3 anos). O número médio de problemas por pessoa foi de 1,6, sendo superior nos homens (1,8). A gravidade da doença também foi maior nos homens. O pior prognóstico esteve associado a seis ou mais condições por pessoa. O maior preditor de gravidade da doença foi o número de problemas, seguido da demência e diabetes. Discussão: Os resultados parecem confirmar a diferença entre sexos quanto ao padrão de morbilidade. O número de condições por pessoa foi o maior preditor de gravidade da doença, particularmente a presença de seis ou mais condições por pessoa. Conclusão: A principal limitação identificada foi o uso das mesmas condições médicas para medir a multimorbilidade e a gravidade da doença. Outros estudos e modelos de análise devem explorar a complexidade do fenómeno da multimorbilidade.

The current and future burden of heart failure in Portugal.

AIMS: Heart failure (HF) is a clinical syndrome with significant social and economic burden. We aimed to estimate the burden of HF in mainland Portugal over a 22-year time horizon, between 2014 and 2036. METHODS AND RESULTS: Heart failure burden was measured in disability-adjusted life years (DALYs), resulting from the sum of years of life lost (YLL) due to premature death and years lost due to disability (YLD). YLL were estimated based on the Portuguese mortality rates reported by the European Detailed Mortality Database. For YLD, disease duration and the overall incidence were estimated using an epidemiological model developed by the World Health Organization (DISMOD II). Disability weights were retrieved from published literature. The impact of ageing was estimated with a shift-share analysis using official demographic projections. In 2014, 4688 deaths were attributed to HF, corresponding to 4.7% of the total deaths in mainland Portugal. DALYs totalled 21 162, 53.9% due to premature death (YLL: 11 398) and 46.1% due to disability (YLD: 9765). Considering only population ageing over a 22-year horizon, the deaths and burden of HF are expected to increase by 73.0% and 27.9%, respectively, reaching 8112 deaths and 27 059 DALYs lost due to HF in 2036. DALY's growth is mainly driven by the increase of YLL, whose contribution to overall burden will increase to 62.0%. CONCLUSIONS: Heart failure is an emerging and growing health problem where significant health gains may be obtained. The projected significant increase of HF burden highlights the need to set HF as a priority for healthcare system.

[Morbidity in the Dependent Elderly Cared by Home-Teams of the National Network of Continued Integrated Care in the Lisbon and Tagus Valley: Cross-Sectional Study]. / Morbilidade em Idosos Dependentes ao Cuidado das Equipas Domiciliárias da Rede Nacional de Cuidados Continuados Integrados na Região de Lisboa e Vale do Tejo: Estudo Transversal Observacional.

INTRODUCTION: In Portugal, the National Network of Continuing Integrated Care's mission is to take care of new health and social needs. The aim of the study was to know the disease burden and disability of the elderly (75 and over) cared by the integrated continuing care teams. MATERIAL AND METHODS: A cross-sectional study carried out in a sample of 230 participants, from 25 teams randomly selected in the region of Lisbon and Tagus Valley. Data were collected at the patient's home trough caregiver's interviewing. The variables studied were: socio-demographic; disability determinants; degree (Barthel's scale) and duration of disability; morbidity (diagnoses, number and Charlson index). RESULTS: The study population had: on average 84 years; low or no scholar degree level (88.7%); on average 9.5 problems per person and a Charlson index of 8.48; disability over 42 months (severe in 65.2%). The most frequent disability-determinants were: dementia, stroke and femur fracture. The most frequent diagnoses were: osteoarthritis, hypertension and dementia. DISCUSSION: The results revealed a high disease burden (Charlson of 8.48) and disability. Although the diagnoses were those expected and comparable with the literature, their coexistence was universal, averaging 9.5 per person, affecting different organs/systems. Multimorbidity, coupled with severe disability, leads to clinical and organizational-care challenges, as well as the need for other population base studies. CONCLUSION: The population cared by the integrated continuing care teams is at risk: elderly, with low scholar degree level, with a high disease-burden and disability.

Introdução: Em Portugal, a Rede Nacional de Cuidados Continuados Integrados tem como missão dar resposta às novas necessidades de saúde e sociais. Definiu-se como objetivo do estudo conhecer a carga de doença e de dependência dos idosos (75 e mais anos) ao cuidado das equipas de cuidados continuados integrados. Material e Métodos: Estudo descritivo transversal, numa amostra de 230 participantes, distribuídos por 25 equipas na região de Lisboa e Vale do Tejo, aleatoriamente selecionadas. A colheita de dados decorreu no domicílio dos doentes por entrevista ao cuidador. As variáveis estudadas foram: sociodemográficas; determinantes de incapacidade; grau (escala de Barthel) e duração de dependência; morbilidade (diagnósticos, número e índice de Charlson). Resultados: A população em estudo tinha: em média, 84 anos; baixa escolaridade (88,7%); dependência durante 42 meses, grave em 65,2%; em média, 9,5 diagnósticos por pessoa e um índice de Charlson de 8,48. Os determinantes de incapacidade mais frequentes foram: demência, acidente vascular cerebral e fratura do fémur. Os diagnósticos mais frequentes foram: osteoartrose, hipertensão e demência. Discussão: Os resultados revelaram uma elevada carga de doença (Charlson de 8,48) e de dependência. Apesar dos diagnósticos serem os esperados e comparáveis com os dados da literatura, a coexistência de dois ou mais foi universal, em média 9,5 por pessoa, afetando diferentes aparelhos/sistemas. A multimorbilidade, a par duma elevada dependência, acarreta desafios clínicos e organizacionais, bem como a necessidade de estudos populacionais. Conclusão: A população ao cuidado das equipas de cuidados continuados integrados é de risco: idosa, com baixa escolaridade, com elevada carga de doença e de dependência.